Apixaban (manufacturer's designation BMS-562247-01) is a compound being investigated as an anticoagulant. It acts by inhibiting coagulation factor Xa. It is presently undergoing phase III trials in the prevention of venous thromboembolism, together with a number of related competing compounds, such as rivaroxaban. It is being marketed in a joint venture by Pfizer and Bristol-Myers Squibb.

A 2007 trial showed that apixaban was equivalent to enoxaparin/open-label heparin in preventing thrombosis is patients who had undergone a knee replacement.